EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

14‐Day Vonoprazan–Minocycline Dual Therapy Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Single‐Center Randomized Controlled Noninferiority Trial

Tingting Yang iD, Ruijuan Xin, Yanhong Deng, Jun Liu, Xue Li, Xiaole Guo iD, Linke Ma, Xiaoming Su iD, Yanxia Liu iD, Chengdong Su, Qian Hao, Rui Mu und 7 weitere

Helicobacter · 2026

DOI: 10.1111/hel.70153 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2026. Verfasst von Tingting Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: The Third Clinical Medical College, Ningxia Medical University, Yinchuan, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Sulfonamides, Pyrroles, Anti-Bacterial Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Achievements in Science and Technology Transformation Project of Ningxia Hui Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rescue treatment for Helicobacter pylori infection remains challenging in regions with high antibiotic resistance. Although bismuth‐containing quadruple therapy is widely recommended as an empirical rescue regimen, its medication burden may impair tolerability and adherence. This trial evaluated the efficacy and safety of 14‐day vonoprazan–minocycline dual therapy compared with vonoprazan‐based bismuth‐containing quadruple therapy as empirical rescue treatment. Materials and Methods This single‐center, prospective, open‐label, randomized, controlled, noninferiority trial enrolled 186 adults aged 18–70 years with at least one previous H. pylori eradication failure. Patients were randomly assigned (1:1) to receive 14‐day vonoprazan–minocycline dual therapy or vonoprazan‐, amoxicillin‐, minocycline‐, and bismuth‐containing quadruple therapy. Eradication was assessed by a 13 C urea breath test 4 weeks after treatment. ITT, mITT, and PP analyses were performed, with a prespecified noninferiority margin of −10%.

Results

Eradication rates in the dual therapy and quadruple therapy groups were 89.2% and 91.4% in the ITT analysis (difference, −2.2%; 95% CI, −10.5% to 6.2%; noninferiority p = 0.036), 90.2% and 92.4% in the mITT analysis (difference, −2.2%; 95% CI, −9.7% to 5.3%; noninferiority p = 0.030), and 91.2% and 93.4% in the PP analysis (difference, −2.2%; 95% CI, −9.4% to 5.0%; noninferiority p = 0.024). Noninferiority was demonstrated in the mITT and PP analyses, whereas the ITT result should be interpreted cautiously because the lower 95% CI bound crossed the margin. Adverse events were similar between treatment groups (11.8% vs. 15.1%; χ 2 = 0.416; p = 0.519), and adherence was high in both groups (97.8% vs. 97.8%; p = 1.000).

Conclusions

14‐day vonoprazan–minocycline dual therapy achieved eradication rates comparable to those of bismuth‐containing quadruple therapy, with acceptable safety and high adherence as rescue treatment for H. pylori infection. This simplified regimen may be considered a potential empirical rescue option when susceptibility testing is not readily available, although the ITT noninferiority result warrants cautious interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsSulfonamidesPyrrolesAnti-Bacterial AgentsHelicobacter pyloriMinocyclineBismuthHumansFemaleMiddle AgedDrug Therapy, CombinationAdultMaleTreatment OutcomeAgedProspective StudiesYoung AdultAdolescentAmoxicillin

Stichwörter der Autor:innen

Helicobacter pyloridual therapyminocyclinerescue treatmentvonoprazan

Substanzen

SulfonamidesPyrrolesvonoprazanAnti-Bacterial AgentsMinocyclineBismuthAmoxicillin

Autor:innen und Institutionen

  • The Third Clinical Medical College, Ningxia Medical University, Yinchuan, China.
  • Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Affiliated People's Hospital of Ningxia Medical University, Yinchuan, China.

ORCID-Profile: Tingting Yang, Xiaole Guo, Xiaoming Su, Yanxia Liu, Shengjuan Hu

Förderung

  • Key Achievements in Science and Technology Transformation Project of Ningxia Hui Autonomous Region

Zitieren

APA

Yang, T., Xin, R., Deng, Y., Liu, J., Li, X., Guo, X., Ma, L., Su, X., Liu, Y., Su, C., Hao, Q., Mu, R., Li, X., Wang, P., Li, Y., Zhang, X., Li, Q., Wu, Y., & Hu, S. (2026). 14‐Day Vonoprazan–Minocycline Dual Therapy Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Single‐Center Randomized Controlled Noninferiority Trial. Helicobacter. https://doi.org/10.1111/hel.70153

Vancouver

Yang T, Xin R, Deng Y, Liu J, Li X, Guo X, et al. 14‐Day Vonoprazan–Minocycline Dual Therapy Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Single‐Center Randomized Controlled Noninferiority Trial. Helicobacter. 2026. doi:10.1111/hel.70153

BibTeX
@article{Yang2026,
  author = {Yang, Tingting and Xin, Ruijuan and Deng, Yanhong and Liu, Jun and Li, Xue and Guo, Xiaole and Ma, Linke and Su, Xiaoming and Liu, Yanxia and Su, Chengdong and Hao, Qian and Mu, Rui and Li, Xiaofei and Wang, Pengda and Li, Yanling and Zhang, Xue and Li, Qingrui and Wu, Yuting and Hu, Shengjuan},
  title = {14‐Day Vonoprazan–Minocycline Dual Therapy Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Single‐Center Randomized Controlled Noninferiority Trial},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70153}
}
Kostenlos starten →